Navigation Links
NxStage Announces FDA Clearance for New High Flow Capabilities with NxStage System One
Date:4/30/2013

LAWRENCE, Mass., April 30, 2013 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that the U.S. Food and Drug Administration (FDA) has cleared new high flow capabilities with the NxStage System One™, the only truly portable hemodialysis system cleared for home use. With this clearance, the Company expects to begin offering its System One with new higher flow capabilities in the United States later this year.

(Logo:  http://photos.prnewswire.com/prnh/20110503/MM94799LOGO)

The new higher flow capabilities for the System One enable increased dialysate flow rates, allowing nephrologists expanded possibilities to adjust the duration and frequency of patient prescriptions. Patients can now enjoy the benefits of home hemodialysis and have even greater treatment flexibility based on their clinical and lifestyle needs.

"This latest regulatory milestone reflects strong and systematic execution against our product pipeline," said Jeffrey Burbank , Chief Executive Officer, NxStage Medical, Inc. "With this new capability, NxStage therapy may be prescribed less frequently, for example 3 times per week or every other day, at treatment times consistent with those that patients and physicians experience in-center today.  We're strong believers in longer and more frequent dialysis for the clinical benefits; still, high flow opens the NxStage solution more broadly to the patient segment that wants the benefits of home, but at in-center frequency."

NxStage's high flow capabilities also received CE mark approval in February 2013.

About NxStage Medical Inc.

NxStage is a medical device company, headquartered in <
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. NxStage Names Robert G. Funari Chairman Of The Board
2. NxStage Completes Move to Direct Sales In UK
3. NxStage Educational Reception at Annual Dialysis Conference Features Celebrity and Former NxStage User Stephen Furst
4. NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results
5. NxStage Announces CE Mark Approval, First Clinical Use of its Single Needle for Dialysis Patients
6. NxStage Announces CE Mark Approval for New High Flow Capabilities with System One
7. NxStage Announces CE Mark Approval for Nocturnal Home Hemodialysis
8. NxStage Initiates 2013 Call to Action Campaign with Launch of Hemodialysis At Home: A Better Way For a Better Life
9. NxStage Home Hemodialysis Patient Awareness Tour Kicks Off January 29th
10. Robert Funari Joins NxStage Board of Directors
11. NxStage Announces Fourth Quarter 2012 Investor Conference Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... YORK , March 27, 2015  Delcath ... pharmaceutical and medical device company focused on oncology ... and metastatic liver cancers, announces the reporting of ... Company,s Melphalan Hydrochloride for Injection with the Delcath ... a poster presentation at the Society of Surgical ...
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
(Date:3/26/2015)... OAK, Mich. , March 26, 2015 ... have performed the Midwest,s first commercial implant of ... Administration for patients with non-valvular atrial fibrillation. The Watchman ... long-term use of blood-thinning warfarin medication to reduce the ... most common heart rhythm disorder affecting more than 5 ...
Breaking Medicine Technology:Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
... May 24, 2011 The National Community ... Competition and Consumer Choice Act of 2011 , ... the pharmacy of their choice, eliminate needless pharmaceutical ... abusive pharmacy audits. (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ...
... May 24, 2011 A coalition of advocacy groups and ... for the District of Columbia Circuit to compel the Obama ... marijuana rescheduled under the provisions of the Controlled Substances Act ... would enable states with medical marijuana laws to expedite efforts ...
Cached Medicine Technology:Community Pharmacists Endorse Bipartisan Pharmacy Competition and Consumer Choice Act 2Community Pharmacists Endorse Bipartisan Pharmacy Competition and Consumer Choice Act 3Federal Court Asked to Compel Decision in Marijuana Scheduling Action 2Federal Court Asked to Compel Decision in Marijuana Scheduling Action 3
(Date:3/28/2015)... York, New York (PRWEB) March 28, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) involving devices manufactured by C.R. Bard, ... litigation underway in U.S. District Court, Southern District ... S. Grand, is serving on the Plaintiffs’ Steering ... 24th, the Court has granted certain defendants named ...
(Date:3/28/2015)... An article in Fortune on Monday, March ... to organizations that deal with PCI (Payment Card Information); ... security, is worsening . Using numbers from Verizon’s ... category out of the twelve measured improved, barring one ... craziness that has gone on in the retail industry ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... injuries is a growing field in orthopaedic medicine. While ... labral tear to confirm the pain etiology, research presented ... ( AOSSM ) Specialty Day suggests that pain relief ... following arthroscopic hip surgery. , “Our study looked ...
(Date:3/28/2015)... Andrew Hawley of Vintage Rock Posters Inc., has ... The Who and the Doors played together at the Singer ... to Hawley, “The Who toured the United States heavily from ... Perhaps the most famous Who poster was a poster created ... on August 2, 1968 at the Singer Bowl in Flushing, ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 The ... method of sustainable health. After 18 years of research ... including professional UFC contenders, Dr. Jon Petrick is excited ... , Just some of the immediate benefits of this ... vitality, increased levels of strength of the immune system, ...
Breaking Medicine News(10 mins):Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For&nbsp;Original 1960's Who Psychedelic Concert Posters. 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2
... NEW YORK, July 13, 2010 The decision regarding ... carcinoma in-situ (DCIS) has long been an area of ... the mortality rates for DCIS remain low, the risk ... treatments following surgery include radiation therapy and hormone treatment. ...
... Science Associates, the company that manages the U.S. ... Engineering Technologies, Inc. (BioSET) of Rockville, Maryland, have ... second-generation technology for designing synthetic peptides that are ... are designed to communicate growth signals to cells ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, July ... knew more than a decade ago that the blockbuster diabetes ... up the information, according to a report published Tuesday in ... trial pitting Avandia against its competitor, Actos, the drug company, ...
... a brooding, complicated people, and ethnographers have confirmed that ... more than Westerners do. But a new University of ... brood, they are less likely than Americans to feel ... on one,s negative feelings tends to impair well-being, but ...
... (July 13, 2010) With current public health threats ... innovations that better predict disease outbreaks have vast potential ... in advance of print on July 6 in ... their vision for the future of disease surveillance, detailing ...
... , TUESDAY, July 13 (HealthDay News) -- Children and ... involuntary tics through self-hypnosis, a small new study suggests. ... too preliminary to indicate whether the strategy actually works. ... the Journal of Developmental & Behavioral Pediatrics , researchers ...
Cached Medicine News:Health News:Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer 2Health News:Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer 3Health News:Brookhaven Lab and BioSET Inc. patent improved growth factor technology 2Health News:Avandia Heart Risks Buried by Drug Company: Report 2Health News:Avandia Heart Risks Buried by Drug Company: Report 3Health News:Brooding Russians: Less distressed than Americans 2Health News:Researchers envision better disease surveillance to improve public health 2Health News:Can Self-Hypnosis Help Tourette Patients Control Tics? 2
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Refkeratometer...
Portable, easy to align, automatic measurement, automatic fogging. Accurate and dependable readings. Infrared printer communication. Rechargeable battery. Integrates with the TRS-2100 and EPIC-2100 r...
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
Medicine Products: